SI3119782T1 - COMPOUNDS 2,7-DIAZASPIRO (3.5) NONANA - Google Patents
COMPOUNDS 2,7-DIAZASPIRO (3.5) NONANA Download PDFInfo
- Publication number
- SI3119782T1 SI3119782T1 SI201530219T SI201530219T SI3119782T1 SI 3119782 T1 SI3119782 T1 SI 3119782T1 SI 201530219 T SI201530219 T SI 201530219T SI 201530219 T SI201530219 T SI 201530219T SI 3119782 T1 SI3119782 T1 SI 3119782T1
- Authority
- SI
- Slovenia
- Prior art keywords
- diazaspiro
- sulfonyl
- nonan
- 6alkyl
- methoxyphenyl
- Prior art date
Links
- DROZYMFJWSYDRY-UHFFFAOYSA-N 2,7-diazaspiro[3.5]nonane Chemical class C1NCC11CCNCC1 DROZYMFJWSYDRY-UHFFFAOYSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract 25
- 239000003814 drug Substances 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 3
- 208000030159 metabolic disease Diseases 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 229910052760 oxygen Inorganic materials 0.000 claims 30
- -1 haloC1-6alkyl Chemical group 0.000 claims 29
- 229910052799 carbon Inorganic materials 0.000 claims 23
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 10
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- LVWKQKBWFTVHLB-UHFFFAOYSA-N 7-(benzenesulfonyl)-n-(3-fluorophenyl)-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound FC1=CC=CC(NC(=O)N2CC3(C2)CCN(CC3)S(=O)(=O)C=2C=CC=CC=2)=C1 LVWKQKBWFTVHLB-UHFFFAOYSA-N 0.000 claims 5
- SGODQWIOWBOYKT-UHFFFAOYSA-N 7-(benzenesulfonyl)-n-phenyl-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1C2(CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)CN1C(=O)NC1=CC=CC=C1 SGODQWIOWBOYKT-UHFFFAOYSA-N 0.000 claims 5
- BLOKECMLIIWMCH-UHFFFAOYSA-N 7-(benzenesulfonyl)-n-propan-2-yl-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC21CCN(S(=O)(=O)C=1C=CC=CC=1)CC2 BLOKECMLIIWMCH-UHFFFAOYSA-N 0.000 claims 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- GVNJESYLNCMALL-UHFFFAOYSA-N n-(3-cyanophenyl)-7-methylsulfonyl-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC11CN(C(=O)NC=2C=C(C=CC=2)C#N)C1 GVNJESYLNCMALL-UHFFFAOYSA-N 0.000 claims 4
- RPFCWYZXPVGZMD-UHFFFAOYSA-N n-(3-fluorophenyl)-7-methylsulfonyl-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC11CN(C(=O)NC=2C=C(F)C=CC=2)C1 RPFCWYZXPVGZMD-UHFFFAOYSA-N 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- MIPCJURDXWBZGS-UHFFFAOYSA-N 7-methylsulfonyl-n-phenyl-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC11CN(C(=O)NC=2C=CC=CC=2)C1 MIPCJURDXWBZGS-UHFFFAOYSA-N 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- BCYYATIMCMWEAV-UHFFFAOYSA-N n-(4-methoxyphenyl)-7-methylsulfonyl-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1CC2(CCN(CC2)S(C)(=O)=O)C1 BCYYATIMCMWEAV-UHFFFAOYSA-N 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 2
- IJMSCUUGZYBRML-UHFFFAOYSA-N 2h-benzotriazol-5-yl-[7-[2-(3-chlorophenyl)ethylsulfonyl]-2,7-diazaspiro[3.5]nonan-2-yl]methanone Chemical compound ClC1=CC=CC(CCS(=O)(=O)N2CCC3(CN(C3)C(=O)C3=CC4=NNN=C4C=C3)CC2)=C1 IJMSCUUGZYBRML-UHFFFAOYSA-N 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- VIFSDEIEVJLEFA-UHFFFAOYSA-N 7-(benzenesulfonyl)-n-(4-methoxyphenyl)-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1CC2(CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)C1 VIFSDEIEVJLEFA-UHFFFAOYSA-N 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000000501 Lipidoses Diseases 0.000 claims 2
- 206010024585 Lipidosis Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- KCVKVMKMXZXHEN-UHFFFAOYSA-N 2-methylnonanamide Chemical compound CCCCCCCC(C)C(N)=O KCVKVMKMXZXHEN-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- BSZDGZNXEHKOFN-UHFFFAOYSA-N 7-[4-(difluoromethoxy)phenyl]sulfonyl-2-(4-methoxyphenyl)sulfonyl-2,7-diazaspiro[3.5]nonane Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OC)CC1)F BSZDGZNXEHKOFN-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- YCBIHKFWSRJXRS-UHFFFAOYSA-N C(C)OC1=C(C#N)C=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 Chemical compound C(C)OC1=C(C#N)C=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 YCBIHKFWSRJXRS-UHFFFAOYSA-N 0.000 claims 1
- FKCLZIVMKRFCRZ-UHFFFAOYSA-N C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)C Chemical compound C(C)OC1=C(C=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)C FKCLZIVMKRFCRZ-UHFFFAOYSA-N 0.000 claims 1
- WJXUIGMNGALNNT-UHFFFAOYSA-N C(C)OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OC)CC1 Chemical compound C(C)OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OC)CC1 WJXUIGMNGALNNT-UHFFFAOYSA-N 0.000 claims 1
- HBLZORMEGDDHIS-UHFFFAOYSA-N C(CCC)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound C(CCC)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC HBLZORMEGDDHIS-UHFFFAOYSA-N 0.000 claims 1
- JYEGKASWJXCIKA-UHFFFAOYSA-N C1(CC1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound C1(CC1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC JYEGKASWJXCIKA-UHFFFAOYSA-N 0.000 claims 1
- CMMABCBPOOMCOE-UHFFFAOYSA-N C1(CCCCC1)CS(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 Chemical compound C1(CCCCC1)CS(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 CMMABCBPOOMCOE-UHFFFAOYSA-N 0.000 claims 1
- OUVOUIDJFKYNMR-UHFFFAOYSA-N CC(=O)NC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 Chemical compound CC(=O)NC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 OUVOUIDJFKYNMR-UHFFFAOYSA-N 0.000 claims 1
- VNIAWHHUQWYCOJ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 Chemical compound CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 VNIAWHHUQWYCOJ-UHFFFAOYSA-N 0.000 claims 1
- YKLHLZIAFZPUSO-UHFFFAOYSA-N CC1=C(C=CC=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 Chemical compound CC1=C(C=CC=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 YKLHLZIAFZPUSO-UHFFFAOYSA-N 0.000 claims 1
- ARHGNEIOPCFZNY-UHFFFAOYSA-N CC1=CC=CC(=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 Chemical compound CC1=CC=CC(=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 ARHGNEIOPCFZNY-UHFFFAOYSA-N 0.000 claims 1
- KGUKWEDPHVNDKQ-UHFFFAOYSA-N CCC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 Chemical compound CCC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 KGUKWEDPHVNDKQ-UHFFFAOYSA-N 0.000 claims 1
- GCUZZTPZZPRPJE-UHFFFAOYSA-N COC(C=C1)=CC=C1S(N1CCC(C2)(CN2C2=NSC=N2)CC1)(=O)=O Chemical compound COC(C=C1)=CC=C1S(N1CCC(C2)(CN2C2=NSC=N2)CC1)(=O)=O GCUZZTPZZPRPJE-UHFFFAOYSA-N 0.000 claims 1
- IWOCHYNSRVWKSO-UHFFFAOYSA-N COC1=C(C=CC=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C Chemical compound COC1=C(C=CC=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C IWOCHYNSRVWKSO-UHFFFAOYSA-N 0.000 claims 1
- MHRQDCKRJIRAFO-UHFFFAOYSA-N COC1=C(C=CC=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C Chemical compound COC1=C(C=CC=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C MHRQDCKRJIRAFO-UHFFFAOYSA-N 0.000 claims 1
- RGIRIWHIJQNILO-UHFFFAOYSA-N COC1=CC(=C(OC)C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 Chemical compound COC1=CC(=C(OC)C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(CC3=CC=C(F)C=C3)=NS2)CC1 RGIRIWHIJQNILO-UHFFFAOYSA-N 0.000 claims 1
- OKEXLHLXTKKBHV-UHFFFAOYSA-N COC1=CC=C(C=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C Chemical compound COC1=CC=C(C=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C OKEXLHLXTKKBHV-UHFFFAOYSA-N 0.000 claims 1
- HBICPWLQJPIWBY-UHFFFAOYSA-N COC1=CC=C(C=C1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound COC1=CC=C(C=C1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC HBICPWLQJPIWBY-UHFFFAOYSA-N 0.000 claims 1
- WPJNCPYUPFONJY-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC WPJNCPYUPFONJY-UHFFFAOYSA-N 0.000 claims 1
- UPGFIQGDOOBHOO-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)C2(CC2)C2=CC=CC=C2)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)C2(CC2)C2=CC=CC=C2)CC1 UPGFIQGDOOBHOO-UHFFFAOYSA-N 0.000 claims 1
- NXFYZSYJDHEWNL-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)C2(CCCC2)C2=CC=CC=C2)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)C2(CCCC2)C2=CC=CC=C2)CC1 NXFYZSYJDHEWNL-UHFFFAOYSA-N 0.000 claims 1
- GNFDJAVFXWIPJF-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)C2CCCC3=CC=CC=C23)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)C2CCCC3=CC=CC=C23)CC1 GNFDJAVFXWIPJF-UHFFFAOYSA-N 0.000 claims 1
- KAPDTSWYWZAFOA-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)CC2=CC=CC=C2)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)CC2=CC=CC=C2)CC1 KAPDTSWYWZAFOA-UHFFFAOYSA-N 0.000 claims 1
- YTTDVPXXNPDYCY-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(C)(C2=C(C=CC=C2)C)C)=O)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(C)(C2=C(C=CC=C2)C)C)=O)CC1 YTTDVPXXNPDYCY-UHFFFAOYSA-N 0.000 claims 1
- LNQNWOWHSWIIRH-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(C)(C2=CC=CC=C2)C)=O)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(C)(C2=CC=CC=C2)C)=O)CC1 LNQNWOWHSWIIRH-UHFFFAOYSA-N 0.000 claims 1
- NBKMIUIPMUBVNF-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(C)(OCC=2C=NC=CC2)C)=O)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(C)(OCC=2C=NC=CC2)C)=O)CC1 NBKMIUIPMUBVNF-UHFFFAOYSA-N 0.000 claims 1
- ZBAGHHKSZNNJHX-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(CC)C2=CC=CC=C2)=O)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C(C(CC)C2=CC=CC=C2)=O)CC1 ZBAGHHKSZNNJHX-UHFFFAOYSA-N 0.000 claims 1
- NKLCNUKMNRQZRW-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)C2=NC=CN=C2)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)C2=NC=CN=C2)CC1 NKLCNUKMNRQZRW-UHFFFAOYSA-N 0.000 claims 1
- BDSJGGRIHAPFBR-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC(F)(F)F)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC(F)(F)F)CC1 BDSJGGRIHAPFBR-UHFFFAOYSA-N 0.000 claims 1
- GELNOZSZHVTGCZ-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC(=CC=C2)C(F)(F)F)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC(=CC=C2)C(F)(F)F)CC1 GELNOZSZHVTGCZ-UHFFFAOYSA-N 0.000 claims 1
- QAVYZXZDDDXRSX-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OCCC)CC1 Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OCCC)CC1 QAVYZXZDDDXRSX-UHFFFAOYSA-N 0.000 claims 1
- TWKOSYIWUOMPAA-UHFFFAOYSA-N COC=1C=C(C=CC1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C Chemical compound COC=1C=C(C=CC1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C TWKOSYIWUOMPAA-UHFFFAOYSA-N 0.000 claims 1
- MKLZHBHKFDSLKI-UHFFFAOYSA-N COC=1C=C(C=CC1OC)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 Chemical compound COC=1C=C(C=CC1OC)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 MKLZHBHKFDSLKI-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- LPSACHJSFOMFJU-UHFFFAOYSA-N ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC(F)F)C=C1 Chemical compound ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC(F)F)C=C1 LPSACHJSFOMFJU-UHFFFAOYSA-N 0.000 claims 1
- SEXYLGLCRBKDSG-UHFFFAOYSA-N ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC)C=C1 Chemical compound ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC)C=C1 SEXYLGLCRBKDSG-UHFFFAOYSA-N 0.000 claims 1
- FOJUJIINLBTAJN-UHFFFAOYSA-N ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OCC)C=C1 Chemical compound ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OCC)C=C1 FOJUJIINLBTAJN-UHFFFAOYSA-N 0.000 claims 1
- NSEJMIOVWBMNPE-UHFFFAOYSA-N ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)SC)C=C1 Chemical compound ClC1=CC2=C(N=C(S2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)SC)C=C1 NSEJMIOVWBMNPE-UHFFFAOYSA-N 0.000 claims 1
- CBXZPLDWKXBERR-UHFFFAOYSA-N ClC1=CC=C(C=C1)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound ClC1=CC=C(C=C1)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC CBXZPLDWKXBERR-UHFFFAOYSA-N 0.000 claims 1
- YVKLSDAZOZVARJ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C Chemical compound ClC1=CC=C(C=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C YVKLSDAZOZVARJ-UHFFFAOYSA-N 0.000 claims 1
- WWFKCCYTJIMGCT-UHFFFAOYSA-N ClC1=CC=C(C=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C Chemical compound ClC1=CC=C(C=C1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C WWFKCCYTJIMGCT-UHFFFAOYSA-N 0.000 claims 1
- FUFXRENEHKFGGU-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound ClC1=CC=C(C=C1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC FUFXRENEHKFGGU-UHFFFAOYSA-N 0.000 claims 1
- BMMMMMGXUXSVHE-UHFFFAOYSA-N ClC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC BMMMMMGXUXSVHE-UHFFFAOYSA-N 0.000 claims 1
- SBNKHEOMPLMQND-UHFFFAOYSA-N ClC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC(F)F Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC(F)F SBNKHEOMPLMQND-UHFFFAOYSA-N 0.000 claims 1
- ARRCLBFPEYIILR-UHFFFAOYSA-N ClC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OC(F)F)CC1 Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OC(F)F)CC1 ARRCLBFPEYIILR-UHFFFAOYSA-N 0.000 claims 1
- IREUDAAOOYWULS-UHFFFAOYSA-N ClC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OC)CC1 Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OC)CC1 IREUDAAOOYWULS-UHFFFAOYSA-N 0.000 claims 1
- VYWDYJVCSHNKBH-UHFFFAOYSA-N ClC=1C=C(C=CC1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C Chemical compound ClC=1C=C(C=CC1)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C VYWDYJVCSHNKBH-UHFFFAOYSA-N 0.000 claims 1
- FKNFYRJZSSGLOL-UHFFFAOYSA-N ClC=1C=C(C=CC1OC)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 Chemical compound ClC=1C=C(C=CC1OC)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1 FKNFYRJZSSGLOL-UHFFFAOYSA-N 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- FOQBYVDWBXOZNI-UHFFFAOYSA-N FC(CCC(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(F)F Chemical compound FC(CCC(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(F)F FOQBYVDWBXOZNI-UHFFFAOYSA-N 0.000 claims 1
- NCXCRQPJGOWAKG-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)F)F Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)F)F NCXCRQPJGOWAKG-UHFFFAOYSA-N 0.000 claims 1
- BRPHIGYNRPZGRI-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC(F)F)F Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC(F)F)F BRPHIGYNRPZGRI-UHFFFAOYSA-N 0.000 claims 1
- RYEYMGSSZMPGKR-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)F Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)F RYEYMGSSZMPGKR-UHFFFAOYSA-N 0.000 claims 1
- VTCARPRLFCLVRM-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OCC)F Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OCC)F VTCARPRLFCLVRM-UHFFFAOYSA-N 0.000 claims 1
- PAHPOBPUZWMFHB-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)F Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)F PAHPOBPUZWMFHB-UHFFFAOYSA-N 0.000 claims 1
- LUCQFBXRZBQLOO-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)F)CC1)F Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)F)CC1)F LUCQFBXRZBQLOO-UHFFFAOYSA-N 0.000 claims 1
- OZVDGJQFSYVGBL-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OCC)CC1)F Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)N1CCC2(CN(C2)S(=O)(=O)C2=CC=C(C=C2)OCC)CC1)F OZVDGJQFSYVGBL-UHFFFAOYSA-N 0.000 claims 1
- GCHNQJRLGFWEOP-UHFFFAOYSA-N FC1=CC=C(C=C1)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound FC1=CC=C(C=C1)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC GCHNQJRLGFWEOP-UHFFFAOYSA-N 0.000 claims 1
- BTIMFMJOJNESEZ-UHFFFAOYSA-N FC1=CC=C(C=C1)C(C)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound FC1=CC=C(C=C1)C(C)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC BTIMFMJOJNESEZ-UHFFFAOYSA-N 0.000 claims 1
- AWBBBCUMQACTMS-UHFFFAOYSA-N FC1=CC=C(C=C1)C1(CC1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound FC1=CC=C(C=C1)C1(CC1)C1=NSC(=N1)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC AWBBBCUMQACTMS-UHFFFAOYSA-N 0.000 claims 1
- MSNBLGNOQYMARN-UHFFFAOYSA-N FC1=CC=C(C=C1)CC(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound FC1=CC=C(C=C1)CC(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC MSNBLGNOQYMARN-UHFFFAOYSA-N 0.000 claims 1
- LOWQVAVOFYORHV-UHFFFAOYSA-N FC1=CC=C(C=C1)CCC(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound FC1=CC=C(C=C1)CCC(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC LOWQVAVOFYORHV-UHFFFAOYSA-N 0.000 claims 1
- MGTLXGAPIBVJJM-UHFFFAOYSA-N FC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound FC1=CC=C(C=C1)S(=O)(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC MGTLXGAPIBVJJM-UHFFFAOYSA-N 0.000 claims 1
- NHDXAAZOXIDDCD-QHCPKHFHSA-N FC1=CC=C(C=C1)[C@@H](C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C(C)C Chemical compound FC1=CC=C(C=C1)[C@@H](C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C(C)C NHDXAAZOXIDDCD-QHCPKHFHSA-N 0.000 claims 1
- NZLNUUOCILWKIP-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=C(F)C=C(F)C=C2)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=C(F)C=C(F)C=C2)C=C1 NZLNUUOCILWKIP-UHFFFAOYSA-N 0.000 claims 1
- OZZZUBJFLNBQJC-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=C(F)C=CC(F)=C2)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=C(F)C=CC(F)=C2)C=C1 OZZZUBJFLNBQJC-UHFFFAOYSA-N 0.000 claims 1
- OYSRCMPJJXCVNZ-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=C(F)C=CC=C2F)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=C(F)C=CC=C2F)C=C1 OYSRCMPJJXCVNZ-UHFFFAOYSA-N 0.000 claims 1
- ZZSRGAFDZYTATI-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=CC(F)=C(F)C=C2)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=CC(F)=C(F)C=C2)C=C1 ZZSRGAFDZYTATI-UHFFFAOYSA-N 0.000 claims 1
- KGSXXXHFKYXREK-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=CC(F)=CC(F)=C2)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=CC(F)=CC(F)=C2)C=C1 KGSXXXHFKYXREK-UHFFFAOYSA-N 0.000 claims 1
- ZHHZMNSJXBYZRK-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=CC=CN=C2)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C2=CC=CN=C2)C=C1 ZHHZMNSJXBYZRK-UHFFFAOYSA-N 0.000 claims 1
- KZDJTYVZHYMSEF-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=C(C=CC(=C3)C)OC)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=C(C=CC(=C3)C)OC)C=C1 KZDJTYVZHYMSEF-UHFFFAOYSA-N 0.000 claims 1
- VBZJAYIVAIZRNH-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=C(C=CC=C3)F)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=C(C=CC=C3)F)C=C1 VBZJAYIVAIZRNH-UHFFFAOYSA-N 0.000 claims 1
- IBGUUOJIZABMBL-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=C(C=CC=C3)OC)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=C(C=CC=C3)OC)C=C1 IBGUUOJIZABMBL-UHFFFAOYSA-N 0.000 claims 1
- WOLUAYBJCUIXBA-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=C(C=C3)OC)C)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=C(C=C3)OC)C)C=C1 WOLUAYBJCUIXBA-UHFFFAOYSA-N 0.000 claims 1
- NWWKDZWJPPIOIM-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)C(F)(F)F)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)C(F)(F)F)C=C1 NWWKDZWJPPIOIM-UHFFFAOYSA-N 0.000 claims 1
- LUGMFRPNCUQLKE-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)F)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)F)C=C1 LUGMFRPNCUQLKE-UHFFFAOYSA-N 0.000 claims 1
- HTUHGBVVRFBMBV-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)OC)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)OC)C=C1 HTUHGBVVRFBMBV-UHFFFAOYSA-N 0.000 claims 1
- SZIAWEOSMMFLOU-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)S(=O)(=O)C)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC(=CC=C3)S(=O)(=O)C)C=C1 SZIAWEOSMMFLOU-UHFFFAOYSA-N 0.000 claims 1
- BPFDKAMKTZPMCB-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)C(F)(F)F)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)C(F)(F)F)C=C1 BPFDKAMKTZPMCB-UHFFFAOYSA-N 0.000 claims 1
- MFKUOLWDEMNNCK-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC)C=C1 MFKUOLWDEMNNCK-UHFFFAOYSA-N 0.000 claims 1
- CHALOXAHXLYEFW-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)C)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)C)C=C1 CHALOXAHXLYEFW-UHFFFAOYSA-N 0.000 claims 1
- QOJKVAGOLYLFEQ-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)SC)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)SC)C=C1 QOJKVAGOLYLFEQ-UHFFFAOYSA-N 0.000 claims 1
- RSLPTKGLPBNDSN-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CSC=C3)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CSC=C3)C=C1 RSLPTKGLPBNDSN-UHFFFAOYSA-N 0.000 claims 1
- NPLNYKPPFNYRTB-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3C(=NOC3C)C)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3C(=NOC3C)C)C=C1 NPLNYKPPFNYRTB-UHFFFAOYSA-N 0.000 claims 1
- BABQGEUADARKCS-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3C=NN(C3)C)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3C=NN(C3)C)C=C1 BABQGEUADARKCS-UHFFFAOYSA-N 0.000 claims 1
- IUACQLGQPWARBI-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3SC(=CC3)C)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3SC(=CC3)C)C=C1 IUACQLGQPWARBI-UHFFFAOYSA-N 0.000 claims 1
- UEDFYJYDBAAYGG-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3SC=CC3)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C=3SC=CC3)C=C1 UEDFYJYDBAAYGG-UHFFFAOYSA-N 0.000 claims 1
- UJYLVYMBUSMCAE-UHFFFAOYSA-N FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)N2CCOCC2)C=C1 Chemical compound FC1=CC=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)N2CCOCC2)C=C1 UJYLVYMBUSMCAE-UHFFFAOYSA-N 0.000 claims 1
- XFAQCGUTRRVWKJ-UHFFFAOYSA-N FC=1C=C(C=C(C1)F)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C Chemical compound FC=1C=C(C=C(C1)F)C(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)C XFAQCGUTRRVWKJ-UHFFFAOYSA-N 0.000 claims 1
- NYKXMPTUXNPPRQ-UHFFFAOYSA-N FC=1C=C(C=CC1F)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound FC=1C=C(C=CC1F)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC NYKXMPTUXNPPRQ-UHFFFAOYSA-N 0.000 claims 1
- PTQGGSKKXMQXHZ-UHFFFAOYSA-N FC=1C=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC)C=CC1F Chemical compound FC=1C=C(CC2=NSC(=N2)N2CC3(C2)CCN(CC3)S(=O)(=O)C3=CC=C(C=C3)OC)C=CC1F PTQGGSKKXMQXHZ-UHFFFAOYSA-N 0.000 claims 1
- XPGVUCCPIFURCY-UHFFFAOYSA-N FC=1C=CC(=C(C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)C Chemical compound FC=1C=CC(=C(C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)C XPGVUCCPIFURCY-UHFFFAOYSA-N 0.000 claims 1
- LJEYMKICPHCBQO-UHFFFAOYSA-N FC=1C=CC(=C(C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)OC Chemical compound FC=1C=CC(=C(C1)S(=O)(=O)N1CCC2(CN(C2)C2=NC(=NS2)CC2=CC=C(C=C2)F)CC1)OC LJEYMKICPHCBQO-UHFFFAOYSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 108700006761 Glyceraldehyde-3-phosphate dehydrogenase deficiency Proteins 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- SOVQSORWQGKPMK-UHFFFAOYSA-N O1CCC(C2=CC=CC=C12)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC Chemical compound O1CCC(C2=CC=CC=C12)C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC SOVQSORWQGKPMK-UHFFFAOYSA-N 0.000 claims 1
- TUOBXSSFSWRFQH-UHFFFAOYSA-N OC(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C2=NC=CC=C2 Chemical compound OC(C(=O)N1CC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C=C2)OC)(C)C2=NC=CC=C2 TUOBXSSFSWRFQH-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 208000006058 glyceraldehyde-3-phosphate dehydrogenase deficiency Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- QVNFEIGASNUDJU-UHFFFAOYSA-N n-(4-methoxyphenyl)-2,7-diazaspiro[3.5]nonane-2-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1CC2(CCNCC2)C1 QVNFEIGASNUDJU-UHFFFAOYSA-N 0.000 claims 1
- 208000033510 neuroaxonal dystrophy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000007153 proteostasis deficiencies Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14160344 | 2014-03-17 | ||
| PCT/EP2015/055494 WO2015140132A1 (en) | 2014-03-17 | 2015-03-17 | 2,7-diazaspiro[3.5]nonane compounds |
| EP15710486.0A EP3119782B1 (en) | 2014-03-17 | 2015-03-17 | 2,7-diazaspiro[3.5]nonane compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3119782T1 true SI3119782T1 (en) | 2018-06-29 |
Family
ID=50287962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530219T SI3119782T1 (en) | 2014-03-17 | 2015-03-17 | COMPOUNDS 2,7-DIAZASPIRO (3.5) NONANA |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9617264B2 (show.php) |
| EP (1) | EP3119782B1 (show.php) |
| JP (2) | JP6574438B2 (show.php) |
| CN (1) | CN106103439B (show.php) |
| AU (1) | AU2015233642B2 (show.php) |
| CA (1) | CA2941196C (show.php) |
| DK (1) | DK3119782T3 (show.php) |
| EA (1) | EA032470B1 (show.php) |
| ES (1) | ES2666173T3 (show.php) |
| HR (1) | HRP20180585T1 (show.php) |
| HU (1) | HUE038764T2 (show.php) |
| NO (1) | NO3119782T3 (show.php) |
| PL (1) | PL3119782T3 (show.php) |
| PT (1) | PT3119782T (show.php) |
| RS (1) | RS57129B1 (show.php) |
| SI (1) | SI3119782T1 (show.php) |
| WO (1) | WO2015140132A1 (show.php) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201416352D0 (en) | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
| GB201416351D0 (en) | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Heterocyclic derivatives |
| US11149022B2 (en) | 2017-10-17 | 2021-10-19 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| EP4269394A4 (en) * | 2021-01-29 | 2024-07-24 | Korea Research Institute of Chemical Technology | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM AS ACTIVE INGREDIENT |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080247964A1 (en) * | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| US20080070888A1 (en) | 2006-09-15 | 2008-03-20 | Mckittrick Brian A | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
| BR112012023664B1 (pt) * | 2010-03-19 | 2020-01-28 | Pfizer | Compostos derivados de 2,3-di-hidro-1hinden-1-il-2,7- diazaspiro [3,5] nonano e composiçãofarmacêutica compreendendo os mesmos |
| WO2013155223A1 (en) * | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| BR112014030473A2 (pt) * | 2012-06-13 | 2017-06-27 | Hoffmann La Roche | novo diazaespirocicloalcano e azaespirocicloalcano |
-
2015
- 2015-03-17 NO NO15710486A patent/NO3119782T3/no unknown
- 2015-03-17 ES ES15710486.0T patent/ES2666173T3/es active Active
- 2015-03-17 HR HRP20180585TT patent/HRP20180585T1/hr unknown
- 2015-03-17 DK DK15710486.0T patent/DK3119782T3/en active
- 2015-03-17 HU HUE15710486A patent/HUE038764T2/hu unknown
- 2015-03-17 CN CN201580013644.7A patent/CN106103439B/zh not_active Expired - Fee Related
- 2015-03-17 EA EA201691539A patent/EA032470B1/ru not_active IP Right Cessation
- 2015-03-17 SI SI201530219T patent/SI3119782T1/en unknown
- 2015-03-17 CA CA2941196A patent/CA2941196C/en active Active
- 2015-03-17 RS RS20180427A patent/RS57129B1/sr unknown
- 2015-03-17 PT PT157104860T patent/PT3119782T/pt unknown
- 2015-03-17 PL PL15710486T patent/PL3119782T3/pl unknown
- 2015-03-17 EP EP15710486.0A patent/EP3119782B1/en active Active
- 2015-03-17 JP JP2016557898A patent/JP6574438B2/ja not_active Expired - Fee Related
- 2015-03-17 US US15/121,790 patent/US9617264B2/en not_active Expired - Fee Related
- 2015-03-17 WO PCT/EP2015/055494 patent/WO2015140132A1/en not_active Ceased
- 2015-03-17 AU AU2015233642A patent/AU2015233642B2/en not_active Ceased
-
2017
- 2017-02-15 US US15/433,164 patent/US9750745B2/en not_active Expired - Fee Related
-
2019
- 2019-05-20 JP JP2019094697A patent/JP2019147834A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NO3119782T3 (show.php) | 2018-06-30 |
| HUE038764T2 (hu) | 2018-11-28 |
| RS57129B1 (sr) | 2018-07-31 |
| PL3119782T3 (pl) | 2018-07-31 |
| PT3119782T (pt) | 2018-04-17 |
| CN106103439A (zh) | 2016-11-09 |
| AU2015233642A1 (en) | 2016-09-08 |
| JP2019147834A (ja) | 2019-09-05 |
| EA032470B1 (ru) | 2019-05-31 |
| CA2941196A1 (en) | 2015-09-24 |
| US9617264B2 (en) | 2017-04-11 |
| ES2666173T3 (es) | 2018-05-03 |
| EP3119782B1 (en) | 2018-01-31 |
| JP2017507986A (ja) | 2017-03-23 |
| US20170157137A1 (en) | 2017-06-08 |
| WO2015140132A1 (en) | 2015-09-24 |
| HRP20180585T1 (hr) | 2018-07-13 |
| EP3119782A1 (en) | 2017-01-25 |
| US20170015665A1 (en) | 2017-01-19 |
| JP6574438B2 (ja) | 2019-09-11 |
| US9750745B2 (en) | 2017-09-05 |
| AU2015233642B2 (en) | 2017-08-03 |
| DK3119782T3 (en) | 2018-03-12 |
| EA201691539A1 (ru) | 2017-01-30 |
| CN106103439B (zh) | 2019-03-08 |
| CA2941196C (en) | 2019-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2485114C2 (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| SI3119782T1 (en) | COMPOUNDS 2,7-DIAZASPIRO (3.5) NONANA | |
| RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| RU2344128C2 (ru) | Бензилпиридазиноны как ингибиторы обратной транскриптазы | |
| RU2426731C2 (ru) | Производные арил-изоксазоло-4-ил-оксадиазола | |
| RU2492167C2 (ru) | Производные аминотриазола в качестве агонистов alх | |
| RU2402553C2 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛ-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2 | |
| JP2017522374A5 (show.php) | ||
| JP2009520685A5 (show.php) | ||
| JP2008516986A5 (show.php) | ||
| JP2013515032A5 (show.php) | ||
| RU2485101C2 (ru) | Новое производное пиррола, имеющее в качестве заместителей уреидную и аминокарбонильную группу | |
| RU2008135128A (ru) | Производные спироимидазола в качестве модуляторов ppar | |
| JP2010534647A5 (show.php) | ||
| JP2008520741A5 (show.php) | ||
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| RU2009133794A (ru) | Гербициды на основе замещенного n-оксида пиридина | |
| JP2014526500A5 (show.php) | ||
| JP2005518371A5 (show.php) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| RU2011116230A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| JP2010533158A5 (show.php) | ||
| JP2020516671A5 (show.php) | ||
| PE20081378A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| JP2013519724A5 (show.php) |